Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)
(Stock Code: 897)

POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 7 MARCH 2024

The Board is pleased to announce that the proposed ordinary resolution in respect of the special dividend by way of distribution in specie of shares of Wang On Group Limited (Stock Code: 1222) and shares of China Agri-Products Exchange Limited (Stock Code: 149), and the proposed special resolution in respect of the share premium reduction of the Company as set forth in the SGM Notice were duly passed by the Shareholders at the SGM held on 7 March 2024 by way of a poll.

References are made to (a) the announcement of Wai Yuen Tong Medicine Holdings Limited (the "Company") dated 25 January 2024; and (b) the circular of the Company dated 15 February 2024 (the "Circular") containing the notice dated 15 February 2024 (the "SGM Notice") convening the special general meeting (the "SGM") held on 7 March 2024. Capitalised terms used herein shall have the same meanings as defined in the Circular unless otherwise defined.

POLL RESULTS OF THE SGM

The Board is pleased to announce that the proposed ordinary resolution in respect of the Distribution in Specie and the proposed special resolution in respect of the Share Premium Reduction as set forth in the SGM Notice were duly passed by the Shareholders at the SGM held on 7 March 2024 by way of a poll and the poll results are as follows:

Ordinary resolution set forth in the SGM Notice	Number of Shares (Approximate %)		Total number of Shares voted (%)
	For	Against	, voted (///)
1. (a) To approve the Distribution in Specie (as defined in the SGM Notice); and (b) To authorize any one director of the Company (the "Director(s)") to effect the Distribution in Specie (as defined in the SGM Notice), to do all such acts and things, and to approve, sign and execute (including affixing the common seal of the Company where required) all such documents, as such Director may consider necessary, desirable or expedient, for the purposes of or incidental to the Distribution in Specie (as defined in the SGM Notice). #	821,175,753 (99.99%)	3,270 (0.01%)	821,179,023 (100%)

	Special resolution set forth in the SGM Notice		Number of Shares (Approximate %) For Against		Total number of Shares voted (%)
2.	(a)	To approve the Share Premium Reduction (as defined in the SGM	821,175,753 (99.99%)	3,270 (0.01%)	821,179,023 (100%)
		Notice);	(33.337%)	(0.01%)	(100%)
	(b)	To authorize, approve, confirm and ratify the board of Directors or a committee thereof to apply the entire amount standing to the credit of the contributed surplus account of the Company in such manner as it considers appropriate from time to time, including but not limited to the Distribution in Specie (as defined in the SGM Notice) without further authorization from the shareholders of the Company, and all such actions in relation thereto; and			
	(c)	To generally authorize any Director to carry out all acts and things, and to approve, sign and execute (including affixing the common seal of the Company where required) all such documents, which they may consider appropriate, necessary or desirable to give effect to or to implement the Share Premium Reduction (as defined in the SGM			

^{*}Note: The full text of the above resolutions proposed at the SGM is set out in the SGM Notice.

Tricor Secretaries Limited, the Company's branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the SGM for the purpose of vote-taking.

As at the date of the SGM, the total number of issued Shares was 1,171,102,888, which was the total number of Shares entitling the Shareholders to attend and vote on the above resolutions proposed at the SGM.

As at the date of the SGM, there were no Shares entitling the Shareholders to attend and abstain from voting in favour as set out in Rule 13.40 of the Listing Rules. None of the Shareholders were required under the Listing Rules to abstain from voting or entitled to attend and vote only against the resolutions at the SGM. There were no parties who have stated their intention in the Circular to vote against or abstain from voting on the resolutions who have done so at the SGM. Ms. Law Man Yee, Anita, an executive Director and Mr. Li Ka Fai, David, an independent non-executive Director, attended the SGM in person.

By Order of the Board
WAI YUEN TONG MEDICINE HOLDINGS LIMITED
(位元堂藥業控股有限公司*)
Tang Wai Man

Executive Director

Hong Kong, 7 March 2024

As at the date of this announcement, the Board comprises Mr. Tang Ching Ho, Ms. Tang Wai Man and Ms. Law Man Yee, Anita as executive Directors, and Mr. Siu Man Ho, Simon, Mr. Li Ka Fai, David, Professor Sit Wing Hang and Professor Chan Wing Kwong as independent non-executive Directors.

* For identification purpose only